Vivek Subbiah shared on X:

“Wow! Just when we thought Alphafold 1,2 are groundbreaking, it’s published in Nature via accelerated article preview today!

A paper reports on the ability of AlphaFold 3 to produce highly accurate predictions of the structures of proteins interacting with other biological molecules. This is beyond amazing!!!

AlphaFold 3 is the latest iteration of the artificial intelligence model created by researchers at Google, DeepMind and Isomorphic Labs, demonstrate substantially better accuracy over previous specialist tools.”

Additional information.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.